

CALCIUM DICARBOXYLATE ETHERS. METHODS OF MAKING SAME.
AND TREATMENT OF VASCULAR DISEASE AND DIABETES
THEREWITH

FIELD OF THE INVENTION

5 The present invention relates to 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt (1:1), 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt (1:1) solvates, methods of producing 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt (1:1) in crystalline forms, methods of producing 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt (1:1) alcohol solvates in crystalline forms, and the treatment of disease therewith. In particular, the 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt (1:1) and solvates thereof of the present invention are useful for lowering certain plasma lipids in animals including Lp(a), triglycerides, VLDL-cholesterol, and LDL-cholesterol, as well as elevating HDL cholesterol. The compounds are also useful for treating diabetes mellitus.

BACKGROUND OF THE INVENTION

20 Vascular diseases such as coronary heart disease, stroke, restenosis, and peripheral vascular disease, remain the leading cause of death and disability throughout the world. About 1.5 million people die each year in the United States alone from myocardial infarction resulting from congestive heart failure. While diet and life style can accelerate the onset of vascular diseases, genetic predisposition leading to dyslipidemia is a significant factor in vascular-related disabilities and deaths. "Dyslipidemia" means abnormal levels of lipoproteins in blood plasma.

25 Several risk factors have been associated with increased risk of vascular disease. Among these are the dyslipidemias of high levels of low-density lipoprotein (LDL) and low levels of high-density lipoproteins (HDL). The ratio of

-2-

HDL-cholesterol to LDL-cholesterol is often used to assess the risk of vascular disease. A high ratio of HDL/LDL cholesterol is desirable. Compounds that increase this ratio by either lowering LDL or increasing HDL, or both, therefore are beneficial.

5 Studies also have shown that elevated levels of a modified form of LDL designated as lipoprotein(a), "Lp(a)," are detrimental. Elevated levels of Lp(a) have been associated with the development of atherosclerosis, coronary heart disease, myocardial infarction, stroke, cerebral infarction, and restenosis following balloon angioplasty. In fact, Lp(a) appears to be an excellent predictor of stroke
10 potential. Accordingly, high concentrations of cholesterol in the form of Lp(a) are one of the major factors leading to death from heart disease. Compounds that lower Lp(a) are therefore beneficial.

U.S. Patent No. 5,648,387 discloses 6-(5-carboxy-5-methyl-hexyloxy)-
15 2,2-dimethylhexanoic acid and its effectiveness in lowering plasma concentrations of Lp(a), and in increasing HDL. The formation of pharmaceutically acceptable salts from the carboxylic acid is also described, for example, by reaction with bases including sodium hydroxide, potassium hydroxide, calcium hydroxide, sodium carbonate, triethylamine, pyridine, and ammonia. Owing to the low
20 melting character of the carboxylic acid and the lack of crystallinity and hygroscopic nature of the contemplated salts thereof, drying and crystallization of large quantities such as mass production lots remains inconsistent. Thus, there exists a need for a salt of the carboxyalkyl ether which is effective in raising HDL, lowering plasma Lp(a), which is crystalline so it can be manufactured and
25 processed on a commercial scale, and which is amenable to pharmaceutical formulation for the treatment of vascular disease. This invention provides a salt form that satisfies these needs.


SUMMARY OF THE INVENTION

This invention provides new chemical compounds, which are calcium
30 dicarboxylate ethers. The invention more particularly provides compounds characterized as solvated or unsolvated forms of the monocalcium salt of

-3-

6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid. The calcium salt of this invention is also known as "CI-1027". The invention compounds have

Formula II:



CI-1027

wherein:

R₁ is H or lower alkyl such as methyl, ethyl, 1-propyl, 2-propyl, and 1-butyl, and x is a number from 0 to 10. Preferred compounds are those wherein R₁ is H.

A preferred compound is CI-1027 Crystal Form 1 wherein R₁ is H and x is equivalent to about 3% to about 6% water content and having XRD of Figure 1.

Another preferred compound is CI-1027 Crystal Form 2 wherein R₁ is H and x is equivalent to about 3% to about 6% water content and having XRD of Figure 15.

Also preferred are nonsolvated forms of the salt, i.e., wherein x is zero.

A method of drying the calcium salt from organic alcohols is also provided. A method of crystallizing the monocalcium salt is a further embodiment.

A method of synthesizing the monocalcium dicarboxylate ether salts of Formula II is provided. The method includes exposing the dialkanoic ether acid to calcium oxide as the base in an organic alcoholic solvent. After allowing sufficient time for the reaction to occur, a solid product is removed and dried to yield a calcium dicarboxylate ether salt having a stoichiometric ratio of calcium to dicarboxylate ether of 1:1, solvated with an alcohol R₁OH. The alcohol R₁OH solvate can be removed by drying with humidification of the drying chamber in vacuo. The calcium dicarboxylate ether salt having a stoichiometric ratio of calcium to dicarboxylate ether of 1:1 can be crystallized as a monohydrate by steam crystallization, namely by heating with water/water vapor at between 50°C to 150°C under pressure with agitation followed by vacuum drying. A second

-4-

crystalline hydrate form can be obtained by heating the first form in water for an extended period of time, or alternatively by reacting the free acid of Formula I directly with calcium hydroxide and water at an elevated temperature of about 80°C and recovering the solid by normal filtration.

5 The compounds of the present invention are useful as active ingredients in combination with pharmaceutically acceptable diluents, carriers, and excipients to treat vascular disease. The use of the calcium dicarboxylate ether salt, or a hydrate or alcohol solvate thereof, for the manufacture of a composition for the treatment of dyslipidemia, such as vascular disease, is also described within. The use of the
10 calcium dicarboxylate ether salt and hydrate or alcohol solvate for the preparation of a composition for the treatment of diabetes is also described within.

BRIEF DESCRIPTION OF THE DRAWINGS

Other advantages of the present invention will be readily appreciated as the same become better understood by reference to the following detailed
15 description when considered in connection with the accompanying drawings. In the drawings, the term "d(A)" means the d-spacing in angstroms. "P%" means the percentage of individual peaks relative to the most intense peak, which is equal to 100%. "Area" means area under the curve or peak. "FWHM" means the full width at half maximum measurement.

20 Figure 1 is a two-dimensional drawing of the x-ray powder diffractogram of dicarboxylate ether monocalcium salt CI-1027 hydrate Crystal Form 1.

 Figure 1A are the numerical values given to the peaks shown in Figure 1. (Each of the figures labeled A are the numerical values of the XRD trace to which the figure refers: e.g., 2A, 3A, etc.).

25 Figure 2 is a two-dimensional drawing of the x-ray powder diffractogram of the ethyl alcohol solvate of the dicarboxylate ether monocalcium salt CI-1027.

 Figure 3 is a two-dimensional drawing of the x-ray powder diffractogram of CI-1027 Crystal Form 1 (3.25% water) after humidification and drying of the ethyl alcohol solvate of the dicarboxylate ether monocalcium salt.

Figure 4 is a two-dimensional drawing of the x-ray powder diffractogram of the methyl alcohol solvate of CI-1027.

Figure 5 is a two-dimensional drawing of the x-ray powder diffractogram of CI-1027 hydrate Crystal Form 1 after humidification and drying of the methyl alcohol solvate of the dicarboxylate ether monocalcium salt.

Figure 6 is a two-dimensional drawing of the x-ray powder diffractogram of the 1-propyl alcohol solvate of CI-1027.

Figure 7 is a two-dimensional drawing of the x-ray powder diffractogram of CI-1027 Crystal Form 1 (3.98% water) after humidification and drying of the 1-propyl alcohol solvate.

Figure 8 is a two-dimensional drawing of the x-ray powder diffractogram of the 2-propyl alcohol solvate of CI-1027.

Figure 9 is a two-dimensional drawing of the x-ray powder diffractogram of a compound of Formula II CI-1027 hydrate Crystal Form 1 after humidification and drying of the 2-propyl alcohol solvate of the dicarboxylate ether monocalcium salt.

Figure 10 is a two-dimensional drawing of the x-ray powder diffractogram of the 1-butyl alcohol solvate of CI-1027.

Figure 11 is a two-dimensional drawing of the x-ray powder diffractogram CI-1027 hydrate Crystal Form 1 after humidification and drying of the 1-butyl alcohol solvate.

Figure 12 is a three-dimensional comparison of x-ray powder diffractograms of the (a) methyl alcohol, (b) ethyl alcohol, (c) 1-propyl alcohol, (d) 2-propyl alcohol, and (e) 1-butyl alcohol solvates of the crystalline compounds of the present invention.


Figure 13 is a three-dimensional comparison of x-ray powder diffractograms of the CI-1027 hydrate Crystal Form 1 derived from the solvates (a)-(e) depicted in Figure 12.

Figure 14 is a two-dimensional overlay of the x-ray diffractograms of organic solvent free 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt produced from various alcohol solvates.

Figure 15 is a two-dimensional drawing of the x-ray diffractogram of CI-1027 hydrate (Crystal Form 2) after heating CI-1027 hydrate Crystal Form 1 with water and isolation and drying.

DETAILED DESCRIPTION OF THE INVENTION

The compounds provided by this invention are prepared from a dialkylcarboxylic acid ether precursor. The synthesis of the precursor dialkylcarboxylic acid ether is described in U.S. Patent No. 5,648,387, which is incorporated herein by reference. The precursor dialkylcarboxylic acid ether has the Formula I:




The diacid of Formula I is identified as 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid. It is also known as "72953".

The calcium salts of Formula II that are provided by this invention are prepared by reacting the precursor dialkylcarboxylic acid ether (I) 72953 with a calcium base such as calcium oxide or calcium hydroxide. Calcium oxide is preferred. A small percentage of water can be present in the calcium oxide (up to about 5%). The reaction is preferably carried out in a solvent which dissolves the dialkylcarboxylic acid ether (I) and is at least only minimally reactive towards the calcium base. Preferably, the base such as calcium oxide partially dissolves in the solvent as well. Solvents operative in the present invention are alkanols, illustratively including C₁-C₁₂ alcohols, for example, methyl alcohol, ethyl alcohol, 1-propyl alcohol, 2-propyl alcohol, butanols, pentanols, cyclopentanol, hexanols, cyclohexanol, and the like. Preferably, the solvent is a C₁-C₆ absolute alcohol, and more preferably a C₁-C₄ alcohol.

The reaction of dialkylcarboxylic acid ether (I) with calcium oxide readily occurs at ambient or higher pressure, and a temperature of generally greater than about 25°C is preferred. However, it is appreciated that the reaction is facilitated

-7-

by heating the reaction mixture to the reflux point of the solvent, or even higher under pressure. Agitation further promotes uniform reaction throughout the reaction mixture. In order to assure conversion of most of the dialkylcarboxylic acid ether (I) to the mono-calcium salt, the molar ratio of calcium oxide to dialkylcarboxylic acid ether (I) should be between approximately 0.95 to approximately 1.05 molar equivalents. After allowing sufficient time for the reaction to occur between the dialkylcarboxylic acid ether (I) and the calcium oxide, a solid product is formed and recovered. Typically, the reaction is complete, in refluxing solvent, in from about 4 to about 96 hours. A compound of the present invention results having the following formula:



CI-1027

wherein R₁ is H or lower alkyl inclusive of methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, and x is a number from 0 to about 10. In a preferred embodiment, R₁ is H (i.e., hydrates). Typically, the amount of water present in preferred salt forms ranges from about 3% to about 6% (e.g., x = 0.03-0.06).

Optionally, following the reaction between the dialkylcarboxylic acid ether (I) and the calcium oxide, the reaction can be diluted by addition of a second solvent. The second solvent (also referred to as the work-up solvent) is preferably miscible with the reaction solvent such that any calcium salt dissolved in the reaction solvent tends to precipitate from the solvent mixture, and any unreacted organic materials remain in solution. It is appreciated that cooling the original solvent system or the mixed solvent system containing dialkylcarboxylic acid ether monocalcium salt (II) further induces precipitation. The identity of the added solvent is dictated, in part, by the identity of the reaction solvent. For example, in the case of the alcohols, methyl *tert*-butyl ether is a representative work-up (or second) solvent. Other work-up solvents can include diethyl ether, tetrahydrofuran, and C₅-C₁₂ mixed alkanes. However, any work-up solvent can be used, provided it is one in which the dialkylcarboxylic acid ether monocalcium

-8-

salt (II) is substantially insoluble, and which can be readily removed by drying using normal conditions. Upon isolating the CI-1027 calcium salt, for instance by filtering or centrifuging off the solid product, the salt (II) is optionally washed with fresh work-up solvent, and is thereafter dried to remove the majority of the remaining water and solvent mixture. Drying is facilitated by heating the salt (II) to a temperature greater than room temperature and less than the decomposition temperature of the salt (II). Drying can be with hot air, heated inert gas, or in vacuo. Preferably, the CI-1027 salt (II) is heated to a temperature range from between about 60°C and about 100°C. The product is substantially dry of solvents after about 1 to 3 hours. More preferably, the salt is heated under vacuum to further facilitate removal of the volatile solvents.

Surprisingly, it was discovered that heating and agitating the amorphous form of dialkylcarboxylic acid ether monocalcium salt (II) in the presence of water not only removed volatile solvents, but also caused the dialkylcarboxylic acid ether monocalcium salt (II) to become highly crystalline.

Humidification of the calcium salt (II) in a vacuum tray dryer facilitated the further removal of all volatile solvents to yield a crystalline form of dialkylcarboxylic acid ether calcium salt (II). The humidification can occur before or after complete drying of the dialkylcarboxylic acid ether monocalcium salt (II). Preferably, the solid monocalcium salt (II) is exposed to a humidification process prior to complete drying in order to facilitate removal of the volatile solvents to below the desired limit (e.g., below about 5%) and to promote crystallinity.

Thus, following partial drying of the salt in a heated vacuum chamber, water and water vapor is introduced to the partially dried dialkylcarboxylic acid ether monocalcium salt (II). Both drying operations are preferably done with agitation. After the humidification, vacuum is reapplied until the salt (II) attains a stable weight. The dialkylcarboxylic acid ether monocalcium salt (II) obtained following a humidification process is highly crystalline and has a bulk density following tapping of between about 0.3 g/mL and about 0.52 g/mL, with an average of about 0.4 g/mL. In contrast, the amorphous form of CI-1027 calcium salt (II) has a bulk density of about 0.2 g/mL to about 0.4 g/mL, with an average of about 0.3 gm/mL.

In a preferred embodiment, the invention provides two distinct polymorphs, namely CI-1027 Crystal Form 1 and CI-1027 Crystal Form 2. Heating a suspension of Crystalline Form 1 of the monocalcium salt in water to about 60°C to 90°C for extended periods of time, of about 6 to about 48 hours, converts it to the second crystalline form, designated Crystalline Form 2. The Crystalline Form 2 product can be prepared directly, if desired, by reacting the dialkylcarboxylic acid ether (I) with calcium hydroxide in water. These forms are distinguishable from one another by their respective x-ray powder diffraction patterns, as evidenced in Figures 1 and 15.

Crystal Forms 1 and 2 are preferred embodiments because they are observably less capable of retaining an electrostatic charge than salts of Formula II that are dried without exposure to humidification. The superior crystallinity of dialkylcarboxylic acid ether monocalcium salt (Forms 1 and 2), following the humidification process and a final drying, is indicated by the x-ray diffraction (XRD) analysis. X-ray powder diffractograms of solvated salts (II) are shown in the figures and indicate solvate formation within the solid product from methyl alcohol, ethyl alcohol, 1-propyl alcohol, 2-propyl alcohol, and 1-butanol. Additional analysis on the post-humidification dried dialkylcarboxylic acid ether monocalcium salt (II) is indicative of the formation of a salt which is associated with between about 0.1 and about 1 molar equivalent of water per equivalent of dialkylcarboxylic acid ether calcium salt (II), as shown in Figures 1 and 15, for example.

It is well-established in the art that unique crystal and polymorphic forms of compounds can be characterized by one or more unique 2-theta values in the x-ray diffractogram. While the Figures recite several 2-theta values, a single 2-theta value will suffice to identify a unique structure. Such unique structure forms also are identified by characteristic resonance peaks in the NMR, for instance, in the ^{13}C NMR spectrum.

The invention compounds of Formula II are useful pharmacological agents. The compounds have been shown to raise HDL and to lower triglycerides, LDL, and VLDL (see U.S. Patent No. 5,783,600). They also lower Lp(a)

(U.S. Patent No. 5,750,569), and they can be used to treat noninsulin dependent diabetes mellitus (U.S. Patent No. 5,756,544).

CI-1027 is currently being evaluated for clinical use in treating vascular diseases. Thus, the crystalline forms of this invention are of particular importance since they will facilitate commercial manufacture and use of a life-saving medication. A further embodiment of this invention is a method of treating vascular disease and diabetes comprising administering to a mammal in need of treatment an effective amount of a compound of Formula II. An "effective amount" is the dose required to treat or prevent the vascular disease or diabetes of the mammal. The compounds are typically administered at a dose of about 50 to about 5000 mg/day, more generally about 50 to 2000 mg/day. A commonly employed dosage is from 50 to 900 mg/day. These same dosage levels are employed for the treatment and prevention of vascular disease, as well as for specifically lowering levels of Lp(a) and elevating HDL-cholesterol, and for treating and preventing diabetes.

Further embodiments of this invention are pharmaceutical compositions comprising a compound of Formula II together with pharmaceutically acceptable excipients, carriers, or diluents. The compounds are formulated for convenient oral, parenteral, or rectal administration, with oral delivery being preferred. Typical pharmaceutical carriers and excipients utilized in oral formulations include lactose, sucrose, starches, such as cornstarch and potato starch; cellulose derivatives such as methyl and ethyl cellulose; gelatins; talc; oils such as vegetable oils, sesame oil, cottonseed oil; and glycols such as polyethylene glycol. Oral preparations typically are in the form of tablets, capsules, emulsions, solutions, and the like. Controlled release formulations, for example, using a polymeric matrix or an osmotic pump, or the like, are also utilized. Typical formulations contain from about 5% to 95% by weight of a compound of Formula II administered with the excipient or carrier. Flavoring agents such as cherry flavor or orange flavor are incorporated.

For parenteral administration, the compounds are optionally formulated with diluents such as isotonic saline, 5% aqueous glucose, and the like, for convenient intramuscular and intravenous delivery. The compounds optionally also are formulated with waxes and gels in the form of suppositories. Topical


-11-

compositions, for example creams and skin patches, can also be prepared according to conventional methods.

In order to more fully demonstrate the advantages of the present invention, the following detailed examples are set forth. It is to be understood that the following examples are for illustration only and should not be construed as a limitation on the scope of the present invention. All citations to references, including patents, are incorporated herein by reference.

EXAMPLE 1

Preparation of 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt hydrate, Crystalline Form 1



Pilot Scale Example to prepare CI-1027 hydrate Crystal Form 1 via ethanol solvate.

Charge to 750 L glass-lined still:

6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid; (72953)—54.4 Kg,
179.9 mol;

Calcium Oxide 98%—10.2 Kg, 178.2 mol;

Ethyl Alcohol, pure anhydrous—392 Kg, 497 L.

Start agitation (stirring) and heat mixture to reflux (76-80°C). Reflux reaction

mixture for 96 hours. Cool to 45°C. Charge to reaction mixture:

Methyl tert-Butyl Ether (MTBE)—128 Kg, 163 L.

-12-

Cool reaction mixture to 20°C to 25°C and stir approximately 1 hour. Filter solid product by centrifugation to provide CI-1027 ethanol solvate (Formula II, R₁ is CH₃CH₂-). Wash solid product with:

MTBE—307 Kg, 391 L.

- 5 Discharge product cake from centrifuge. Charge solvent wet product cake (CI-1027 ethanol solvate) to 400 L agitated pan dryer. Seal dryer and apply vacuum on the system. Set jacket temperature for 85°C. Start agitation after approximately 1 hour at 85°C and full vacuum. Stir product at 85°C and full vacuum for 12 to 16 hours. Set jacket temperature to
- 10 100°C. Close valve to vacuum source.

Charge by way of vacuum blank through injection nozzle:

Water, HPLC grade—6.4 Kg.

- Water will vaporize and humidify the system. Stir the sealed, humidified system for 4 hours. Re-apply vacuum and dry product for 18 to 24 hours. Cool
- 15 system to 25°C. Purge off vacuum with nitrogen. Discharge dry product from the dryer to give CI-1027 hydrate Crystal Form 1 as a white solid. Mill dry product through a Fitzmill with a #1A screen (The Fitzmill Company, Elmhurst, Illinois). Overall yield: 55.2 Kg (uncorrected for 4.04% water). 90.9%.

20 **Analytical Results:**

C₁₆H₂₈O₅Ca H₂O—Infrared (KBr): 1107.3, 1416.2, 1477.9, 1552 cm⁻¹

Identification (¹H NMR)—(CDCl₃): δ 7.2, 3.4, 1.5, 1.2.

Identification (HPLC retention time)—Waters Symmetry C18 column;

150 × 4.6 mm: 8.46 minutes

- 25 Assay (HPLC wt/wt %)—99.30%

Ethyl Alcohol Content (wt % VPC)—0.06%

Water Content determined by thermogravimetric analysis (TGA)—3.45%

Calcium Content (by inductively coupled plasma method [ICP], corrected for water)—12.91%

- 30 Sodium Content—0.08%

XRD—CI-1027 hydrate Crystalline Form 1, see Figure 1.

-13-

^{13}C NMR (solid state) in ppm 189.6: 186.2: 71.4: 43.4: 30.1: 28.4: 25.2*: 23.1

The * indicates a resonance considered unique for this Crystal Form 1.

Pilot Scale Data

Upon further scale-up of the foregoing CI-1027 hydrate Crystal Form 1 process, difficulties were encountered in drying the final product. The monocalcium salt ethanol solvate was formed in refluxing ethyl alcohol as described above. The removal of the ethyl alcohol from the isolated CI-1027 hydrate Crystal Form 1 product proved very difficult at larger scale using typical maximum drying conditions (100°C, full vacuum) and vacuum tray dryers. Different types of agitated dryers were investigated. Although some small-scale lots were dried to acceptable levels of ethyl alcohol, the results were inconsistent and the conditions applied were not conducive to further scale-up. See Table A for drying examples. The various lots (all prepared substantially as described above) are identified as "CD-number".

A preferred process for forming the hydrate is to expose the CI-1027 solvate product to humidity. The added humidity greatly accelerates the removal rate of the ethyl alcohol and facilitates production of the hydrate. This method was initially applied to the vacuum tray dryers with some success. The further application to agitated pan dryers resulted in a process whereby the ethyl alcohol was easily removed in a short time period. This humidified drying process produced consistent crystalline product in short cycle times and therefore demonstrates feasibility for large-scale manufacturing use.

The initial drying method, without the use of humidity, produced a CI-1027 hydrate product with an amorphous physical form as determined by x-ray diffraction (for example, Lots CD-2969C-3111 in Table A). The humidification process comprises drying the alcohol solvate at an elevated temperature of about 50°C to about 150°C in the presence of about 80% to about 95% relative humidity. The ethanol solvate from above was dried in a humidified agitated pan dryer to produce a CI-1027 hydrate Crystal Form 1 product with a crystalline form as determined by x-ray diffraction. Subsequently, it was observed that the crystalline form exhibited significant advantages over the amorphous form. The CI-1027 hydrate Crystalline Form 1 (Lots CD-3103-3243 in Table A) has a higher

-14-

bulk density than amorphous CI-1027 as shown in Table B. The bulk density of the amorphous form was observed to be decreasing with increasing production scale. The crystalline form, however, was consistently produced with high bulk density, and is also observably less electrostatic than the amorphous form, a characteristic that greatly improves the handling characteristics of the bulk product. It should be noted that solvent free amorphous CI-1027 product also can be converted directly to CI-1027 hydrate Crystalline Form 1 by exposure to humidification. Solvent content is not required for the conversion to the Crystalline Form 1 product.

In summary, the advantages of the humidification process and resultant crystalline product include the following:

1. The humidification process allows for the effective drying of the CI-1027 hydrate Crystal Form 1 at a large scale. It produces a consistent, substantially alcohol solvent free product in a much shorter time period.
2. The resultant crystalline, alcohol solvent free CI-1027 hydrate Crystal Form 1 product generally exhibits a higher bulk density than amorphous CI-1027. This bulk density has been reasonably consistent upon scale-up, whereas the amorphous bulk density was observed to drop upon scale-up.
3. The resultant crystalline, alcohol free CI-1027 hydrate Crystal Form 1 product is observably less electrostatic than the amorphous product. This greatly improves the handling characteristics of the bulk product in large-scale production operations, and in subsequent fill/finish operations for the pharmaceutical dosage form.

-15-

Table A

Drying Time Experiments/Results

Lot ID	Drying Method	Time (hrs)	Solvent Content
CD-2969C	Vac. Tray Dryer	48	1.12% EtOH
	@ 72°C	24	1.08% EtOH
	@ 80°C	72	0.92% EtOH; 2.84% H ₂ O
CD-3032	Vac. Tray Dryer	24	7.0% EtOH
	@ 82°C	24	6.0% EtOH
Milled here	→ @ 82°C	24	5.5% EtOH
	@ 95°C	24	4.4% EtOH
	@ 95°C	72	0.9% EtOH; 1.24% H ₂ O
CD-3044	Vac. Tray Dryer @ 60°C	24	5.2% EtOH
	@ 82°C	24	4.1% EtOH
	@ 101°C	24	4.1% EtOH
Nitrogen bleed started here	→ @ 102°C	18	2.0% EtOH
	@ 101°C	72	0.2% EtOH
	@ 101°C	72	0.1% EtOH; 1.5% H ₂ O
CD-3055	Vac. Tray Dryer @ 60°C	24	7.7% EtOH
Milled: moved into a rotary dryer here	→ @ 82°C	24	5.5% EtOH
	→ @ 104°C	24	4.7% EtOH
	@ 105°C	24	3.4% EtOH
	@ 104°C	24	2.9% EtOH
	@ 101°C	24	2.5% EtOH
	@ 104°C	24	2.0% EtOH
	@ 101°C	24	2.0% EtOH
Moved to trays	→ @ 103°C	24	0.3% EtOH
	@ 103°C	24	0.1% EtOH; 1.92% H ₂ O

10015537 124701

-16-

Table A (cont'd)

Drying Time Experiments/Results

Lot ID	Drying Method	Time (hrs)	Solvent Content
CD-3082	Vac. Tray Dryer @ 82°C	24	5.97% EtOH
Milled here	→ @ 98°C	24	0.85% EtOH
Added 5 L	→ @ 97°C	24	0.72% EtOH
water in a tray	@ 97°C	24	0.41% EtOH
here	remilled		0.11% EtOH; 1.59% H ₂ O
CD-3089	Agitated Pan Dryer		
	@ 82°C	24	7.1% EtOH
	@ 98°C	24	5.5% EtOH
	@ 100°C	24	5.1% EtOH
Moved to tray	→ @ 100°C	20	1.8% EtOH
dryer. Added	@ 101°C	18	0.22% EtOH
5 L water	@ 100°C	24	0.01% EtOH; 3.02% H ₂ O
CD-3102	Vac. Tray Dryer @ 84°C	20	6.7% EtOH
	@ 95°C	24	3.9% EtOH
	@ 95°C	24	1.77% EtOH
	@ 95°C	24	0.6% EtOH
	@ 95°C	72	ND EtOH; 2.12% H ₂ O
CD-3111	Vac. Tray Dryer @ 81°C	24	5.4% EtOH
10 trays	@ 98°C	24	0.07% EtOH
without covers.	@ 97°C	24	0.05% EtOH
Trays placed at	milled		ND EtOH; 1.94% H ₂ O
top of oven			

10018547, 321704

-17-

Table A (cont'd)

Drying Time Experiments/Results

Lot ID	Drying Method	Time (hrs)	Solvent Content
CD-3103*	Agitated Pan Dryer		
	@ 80°C	24	5.4% EtOH
1 Kg water	→ @ 80°C	24	0.07% EtOH
added here	@ 100°C	24	0.05% EtOH
	milled		0.06% EtOH: 3.7% H ₂ O
CD-3130*	Agitated Pan Dryer		
	@ 85°C	24	5.9% EtOH
2 Kg water	→ @ 80°C	24	0.04% EtOH
added here	@ 100°C	24	0.06% EtOH
	milled		0.08% EtOH: 4.15% H ₂ O
CD-3135*	Agitated Pan Dryer		
	@ 80°C	24	5.76% EtOH
2 Kg water	→ @ 99°C	22	0.02% EtOH
added here	@ 98°C	5.5	0.02% EtOH
	milled		ND EtOH: 4.38% H ₂ O
CD-3172*	Agitated Pan Dryer		
	@ 80°C	20	7.0% EtOH
4 Kg water	→ @ 100-102°C	19	0.2% EtOH
added here	@ 100°C	24	0.2% EtOH
CD-3321A*	Agitated Pan Dryer		
	@ 80-85°C	18	6.27% EtOH
6.4 Kg water	→ @ 96-97°C	27	0.23% EtOH
added here	@ 97-98°C	19	0.06% EtOH

10016517, 424704

-18-

Table A (cont'd)

Drying Time Experiments/Results

Lot ID	Drying Method	Time (hrs)	Solvent Content
CD-3243*	Agitated Pan Dryer		
	@ 85-87°C	19	7.22% EtOH
6.4 Kg water	→ @ 98-99°C	16	0.09% EtOH
added here	@ 99°C	18	0.06% EtOH

The product is amorphous by XRD unless designated with * symbol.

The scale of product from CD-3172 was 35.1 Kg; from CD-3221A was 53.9 Kg;
from CD-3243 was 49.3 Kg.

* Crystalline product by XRD analysis.

The extra drying time in these examples is because of the 24-hour turn around
time for the ethyl alcohol analysis.

10018637 321701

-19-


Table B

Bulk Density Results

Lot ID	Bulk Density		XRD
	Loose (g/mL)	Tapped (g/mL)	
CD-2969C	0.336	0.439	Amorphous
CD-3032	0.239	0.306	Amorphous
CD-3044	0.249	0.279	Amorphous
CD-3055	0.280	0.315	Amorphous
CD-3082	0.234	0.337	Amorphous
CD-3089	0.292	0.337	Amorphous
CD-3102	0.215	0.270	Amorphous
CD-3111	0.218	0.264	Amorphous
CD-3103	0.343	0.484	Crystalline
CD-3130	0.311	0.496	Crystalline
CD-3135	0.242	0.379	Crystalline
CD-3172	0.281	0.438	Crystalline
CD-3221A	0.372	0.521	Crystalline
CD-3243	0.235	0.300	Crystalline

EXAMPLE 2

Preparation of Crystalline 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt, ethyl alcohol solvate



-20-

Standard Laboratory Method

Charge to 500 mL, 3-neck, round bottom flask with heating mantle, reflux condenser, and overhead stirring:

6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid: (72953)—25.0 g.

5 0.08267 mol;

Calcium Oxide 98%—1.0 equivalent, 0.08267 mol, 4.73 g (corrected for purity):

Ethyl Alcohol—187.5 g, 237 mL.

Start moderate agitation (stirring) and heat mixture to reflux (76-80°C). Reflux reaction mixture for 4 to 24 hours. Cool to about 45°C.

10 Charge to reaction mixture:

MTBE—60.0 g, 79.2 mL.

Cool reaction mixture to 20°C to 25°C and stir approximately 1 hour. Filter off solid product.

Wash solid product with:

15 MTBE—40.0 g, 50 mL.

Dry product at 60°C to 100°C and full vacuum to constant weight. Discharge from dryer. White solid. Overall yield: 21 g (20 g dry basis) (corrected for water and ethyl alcohol content), 80% of title compound.

Analytical Results:

20 Identification (IR)—KBr: 1107.3, 1552 cm⁻¹

Identification (¹H NMR)—(CDCl₃): δ 7.2.

HPLC (Area % CI-1027)—99.738%

Ethyl Alcohol Content (wt % VPC)—1.95%

Water Content (KF titration)—1.73% (avg. of 3)

25 Calcium Content (ICP, corrected for water)—10.82%

XRD—Crystalline solvate, see Figure 2.

¹³C NMR (solid state) in ppm 189.9: 186.7: 71.6: 58.5*: 43.2: 29.9: 23.5

The * indicates a resonance considered unique for this crystal form.

-21-

EXAMPLE 3

Preparation of 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt hydrate, Crystalline Form 1

Standard Laboratory Method (This is a summary of repeated reactions following the same procedure.)

Charge to jacketed 500 mL, 3-neck, round bottom flask with overhead stirrer, vacuum gauge, water injection nozzle, and external temperature bath: 50 g of 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt, ethyl alcohol solvate prepared as described in Example 2.

Seal reactor and start agitation (60-100 rpm). Pull full house vacuum on the system. Set jacket temperature for 60°C. Stir product at 60°C and full vacuum for 18 hours. Close valve to vacuum source. Charge by way of vacuum blank through injection nozzle: Water—20 g.

Water will vaporize and humidify the reaction system. Stir the sealed, humidified system for 4 hours. Reapply vacuum and dry product for 20.5 hours. Cool system to below 30°C and purge off vacuum with nitrogen. Discharge dry product from the reactor. Product is a white chunky solid. Overall yield: 24.89 g of title product.

Analytical Results:

HPLC (Area % CI-1027)—99.725%

Ethyl Alcohol Content (wt % VPC)—0.0%



Water Content (KF titration)—3.25%

XRD analysis established the product to be CI-1027 Crystalline Form 1, see Figure 3.

EXAMPLE 4

Preparation of Crystalline 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt, methyl alcohol solvate

-22-



Standard Laboratory Method

Charge to 500 mL, 3-neck, round bottom flask with heating mantle, reflux condenser, and overhead stirring:

6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid: CI-1027 Step 1
(72953)—25.0 g, 0.08267 mol;

Calcium Oxide 98%—1.0 equivalent, 0.08267 mol, 4.73 g (corrected for purity).

Methyl Alcohol—187.5 g. 237 mol.

Start moderate agitation (50-60 rpm stirring) and heat mixture to reflux (64-66°C).

Reflux reaction mixture for 21 hours. Cool to 45°C. Charge to reaction mixture:

MTBE—60.0 g. 79.2 mL.

Cool reaction mixture to 20°C to 25°C and stir approximately 1 hour. Filter off solid product. Wash solid product with:

MTBE—40.0 g. 50 mL.

Product is white solid with gray chunks—50.87 g

Dry product at 60°C with full vacuum for 3 hours to weight (21.75 g). Dry at 80°C for 16 hours to weight of 16.34 g. Dry at 100°C for 4.5 hours to weight of 10.97 g. Discharge from dryer. Product is a white crystalline solid.

Analytical Results:

HPLC (Area % CI-1027)—99.737%

Water Content (KF titration)—3.36% to 4.94% (range of 3 runs)

-23-

Calcium Content (ICP, corrected for water)—11.00% to 11.22% (water range)

XRD—CI-1027 methyl alcohol crystalline solvate, see Figure 4.

^{13}C NMR (solid state) in ppm: 189.6: 186.2: 71.4: 43.2: 29.6: 23.5

EXAMPLE 5

5 **Preparation of 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt, Crystalline Form 1 from methyl alcohol solvate**

Standard Laboratory Method

Charge to jacketed 500 mL, 3-neck, round bottom flask with overhead stirrer,

vacuum gauge, water injection nozzle, and external temperature bath:

10 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt;
methyl alcohol solvate, prepared in Example 4.

Seal reactor and start agitation (60-100 rpm). Pull full house vacuum on the system. Set jacket temperature for 100°C. Close valve to vacuum source.

Charge by way of vacuum blank through injection nozzle: Water—10 g.

15 Water will vaporize and humidify the system at 100°C. Stir the sealed, humidified system for 60 minutes. Reapply vacuum and dry product for 2 hours. Cool system to 25°C. Purge off vacuum with nitrogen. Discharge dry product from the reactor to provide crystalline white free flowing powder: 4.22 g.

Analytical Results:

20 HPLC (Area % CI-1027)—99.24%

Ethyl Alcohol Content (wt % VPC)—0.0%

Water Content (KF titration)—3.84%

Calcium Content (ICP, corrected for water)—11.52%


XRD—Crystalline Form I, see Figure 5.

25

EXAMPLE 6

Preparation of Crystalline 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt, 1-propyl alcohol solvate

-24-



Standard Laboratory Method

Charge to 500 mL, 3-neck, round bottom flask with heating mantle, reflux condenser, and overhead stirring:

6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid: CI-1027 Step 1
(72953)—25.0 g. 0.08267 mol;

Calcium Oxide 98%—1.0 equivalent, 0.08267 mol, 4.73 g (corrected for purity);
1-Propyl Alcohol—187.5 g, 233 mL.

Start moderate agitation (50 rpm) and heat mixture to reflux (95-98°C). Reflux reaction mixture for 12 hours. Cool to less than 50°C. Charge to reaction mixture:

MTBE—60.0 g. 79.2 mL.

Cool reaction mixture to 20°C to 25°C and stir approximately 1 hour. Filter off solid product. Wash solid product with:

MTBE—40.0 g. 50 mL.

Product is clay-like white solid—69.06 g.

Dry product at 60°C and full vacuum for 16 hours (weight 29.52 g). Dry product at 80°C for 3.5 hours to 23.53 g. Dry product at 100°C for 2 hours to 18.03 g. Discharge from dryer to give white solid.

Analytical Results:

HPLC (Area % CI-1027)—99.064%

1-Propyl Alcohol Content (TGA)—5.99%

Water Content (KF titration)—1.72% (avg. of 2 runs)

-25-

Calcium Content (ICP, corrected for water)—10.73%

XRD—CI-1027 Crystalline 1-propyl alcohol solvate, see Figure 6.

¹³C NMR (solid state) in ppm 189.9: 186.0: 71.6: 43.2: 29.6: 23.8

EXAMPLE 7

5 **Preparation of 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt, Crystalline Form 1 from 1-propyl alcohol solvate**

Standard Laboratory Method

Charge to jacketed 500 mL, 3-neck, round bottom flask with overhead stirrer, vacuum gauge, water injection nozzle, and external temperature bath:

10 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt:
 1-propyl alcohol solvate, prepared in Example 6.

Seal reactor and start agitation (60-100 rpm). Pull full vacuum (best available) on the system. Set jacket temperature for 100°C. Close valve to vacuum source. Charge by way of vacuum blank through injection nozzle:

15 Water—10 g.

Water will vaporize and humidify the system. Stir the sealed, humidified system for 30 minutes. Reapply vacuum and dry product for 2 hours. Cool system to below 25°C. Purge off vacuum with nitrogen. Discharge product from the reactor to provide white coarse powder—10.33 g.

20 **Analytical Results:**

HPLC (Area % CI-1027)—99.519%

1-Propyl Alcohol Content (TGA)—0.0%

Water Content (KF titration)—3.98% (avg. of 2)


Calcium Content (ICP, corrected for water)—10.20%

25 XRD—CI-1027 Crystalline Form 1, see Figure 7.

EXAMPLE 8

Preparation of Crystalline 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt, 2-propyl alcohol solvate

-26-

**Standard Laboratory Method**

Charge to 500 mL, 3-neck, round bottom flask with heating mantle, reflux condenser, and overhead stirring:

6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid: (72953)—25.0 g.
0.08267 mol

Calcium Oxide 98%—1.0 equivalent, 0.08267 mol, 4.73 g (corrected for purity)

2-Propyl Alcohol—187.5 g, 239 mL

Start moderate agitation (50 rpm) and heat mixture to reflux (80-83°C). Reflux reaction mixture for 24 hours. Cool to 40°C. Charge to reaction mixture: MTBE—60.0 g, 79.2 mL.

Cool reaction mixture to 20°C to 25°C and stir approximately 1 hour. Filter off solid product. Wash solid product with:

MTBE—40.0 g, 50 mL.

Product is white solid—50.90 g.

Dry product at 60°C and full vacuum for 3 hours to weight of 28.59 g. Dry at 80°C for 16 hours to 23.27 g. Dry at 100°C for 4 hours to 17.51 g.

Discharge from dryer to provide crystalline white solid.

Analytical Results:

HPLC (Area % CI-1027)—99.315%

2-Propyl Alcohol Content (TGA)—6.12%

Water Content (KF titration)—1.96% (avg. of 3)

Calcium Content (ICP, corrected for water)—10.27%

-27-

XRD—CI-1027 2-propyl alcohol crystalline solvate. see Figure 8.

¹³C NMR (solid state) in ppm 189.4; 187.7; 70.9; 69.4; 66.5; 63.8*; 43.2; 35.0;
30.1; 23.8; 18.7*; 14.3*

The * indicates a resonance considered unique for this form.

5

EXAMPLE 9

Preparation of 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt, Crystalline Form 1 from 2-propyl alcohol solvate

Standard Laboratory Method

Charge to jacketed 500 mL 3-neck round bottom flask with overhead stirrer,

10

vacuum gauge, water injection nozzle, and external temperature bath:

6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt;

2-propyl alcohol solvate, prepared in Example 8.

Seal reactor and start agitation (60-100 rpm). Pull full vacuum on the system. Set

15

jacket temperature for 100°C. Close valve to vacuum source. Charge by

way of vacuum blank through injection nozzle: Water—10 g.

Water will vaporize and humidify the system. Stir the sealed, humidified system

for 60 minutes. Reapply vacuum and dry product for 12 hours. Cool

system to below 30°C. Purge off vacuum with nitrogen. Discharge product

from the reactor to provide a free flowing powder—9.01 g.

20

Analytical Results:

HPLC (Area % CI-1027)—99.611%

2-Propyl Alcohol Content (TGA)—0.0%

Water Content (KF titration)—4.04% (avg. of 2)

Calcium Content (ICP, corrected for water)—10.93%


25

XRD—CI-1027 Crystalline Form 1. see Figure 9.

EXAMPLE 10

Preparation of Crystalline 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt, 1-butyl alcohol solvate

-28-



Standard Laboratory Method

Charge to 500 mL, 3-neck, round bottom flask with heating mantle, reflux condenser, and overhead stirring:

6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid: (72953)—25.0 g,
0.08267 mol;

Calcium Oxide 98%—1.0 equivalent. 0.08267 mol. 4.73 g (corrected for purity);
1-Butyl Alcohol—187.5 g. 231.5 mL.

Start moderate agitation and heat mixture to reflux (117-120°C). Reflux reaction mixture for 12 hours. Cool to less than 50°C. Charge to reaction mixture: MTBE—60.0 g, 79.2 mL.

Cool reaction mixture to 20°C to 25°C and stir approximately 1 hour. Filter off solid product. Wash solid product with: Methyl tert-Butyl Ether—40.0 g, 50 mL.

Product was white coarse solid—44.16 g.

Dry product at 60°C at full vacuum for 16 hours to weight of 29.04 g. Dry at 80°C for 3.5 hours to 23.83 g. Dry at 100°C for 2 hours to weight of 18.43 g. Discharge from dryer to give crystalline white solid.

Analytical Results:

HPLC (Area % CI-1027) — 99.560%

1-Butyl Alcohol Content (TGA)—9.02%

Water Content (KF titration)—1.93% (avg. of 2)

Calcium Content (ICP, corrected for water)—9.65%

-29-

XRD—CI-1027 Crystalline 1-butyl alcohol solvate. see Figure 10.

¹³C NMR (solid state) in ppm 189.9; 186.0; 71.6; 43.2; 29.9; 23.8

EXAMPLE 11

Preparation of 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt, Crystalline Form 1 from 1-butyl alcohol solvate

Standard Laboratory Method

Charge to jacketed 500 mL, 3-neck, round bottom flask with overhead stirrer,

vacuum gauge, water injection nozzle, and external temperature bath:

6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt:

1-butyl alcohol solvate, prepared in Example 10.

Seal reactor and start agitation (60-100 rpm). Pull full vacuum (best available) on the system. Set jacket temperature for 100°C. Close valve to vacuum source. Charge by way of vacuum blank through injection nozzle:

Water—10 g.

Water will vaporize and humidify the system. Stir the sealed, humidified system for 30 minutes. Reapply vacuum and dry product for 2 hours. Cool system to 25°C. Purge off vacuum with nitrogen. Discharge dry product from the reactor to give coarse granular solid—10.35 g.

Analytical Results:

HPLC (Area % CI-1027)—99.374%

1-Butyl Alcohol Content (TGA)—0.0%

Water Content (KF titration)—3.96% (avg. of 3 runs)

Calcium Content (ICP, corrected for water)—10.70%

XRD—CI-1027 Crystalline Form 1. see Figure 11.

EXAMPLE 12

Preparation of 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt. Crystalline Form 2 formed by water digestion

Standard Laboratory Method

Charge to 200 mL round bottom flask:

-30-

6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt:

CI-1027 Crystalline Form 1 prepared using method of Pilot Plant

Example 1 — 24.4 g

Water — 100 g

5 The round bottom flask containing the slurry was attached to a rotary evaporator and a slow rotation initiated (120 rpm). The round bottom flask containing the slurry was then immersed in a water bath set for a temperature of 60°C. The aqueous suspension was stirred under atmospheric pressure for 7 days, and then the mixture was cooled to 20°C to 25°C. The solids were
10 collected by filtration and washed with 50 g of fresh water.

The solid product was dried at 90°C under full vacuum to constant weight to give CI-1027 Crystal Form 2 hydrate as a white solid — 21.3 g, 20.6 g dry basis (corrected for water), 84%.

Analytical Results:

15 HPLC (Area % CI-1027) — 100.06%

Ethyl Alcohol Content (wt % VPC) — 0.04%

Water Content (KF titration) — 3.47%

Calcium Content (ICP, corrected for water) — 10.78%

XRD — CI-1027 hydrate Crystalline Form 2, see Figure 15.


20 ¹³C NMR (solid state) in ppm 190.9: 189.6: 186.2: 120.4: 72.7*: 44.7*: 44.2; 43.0: 42.3: 39.3: 37.9: 31.8: 30.9: 29.6: 27.7: 26.2*: 25.3: 24.0: 22.9: 21.5; and 20.2.

The * indicates a resonance considered unique for this form.

EXAMPLE 13

25 **Preparation of Crystalline 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt, Crystalline Form 2, formed by reaction with calcium hydroxide in water**

-31-



Standard Laboratory Method

Charge to 500 mL 3-neck, round bottom flask with heating mantle, reflux condenser, and overhead stirring:

6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid: (72953)—25.0 g,
0.08267 mol.

Calcium Hydroxide Powder—1.0 equivalent, 0.08267 mol. 6.13 g (uncorrected for purity).

Water—175 g, 175 mL.

Start agitation and heat mixture to 80°C. Stir reaction mixture at 80°C for 12 hours. Cool reaction mixture to 0-5°C. Add 40 mL water to maintain stirrable mixture. Filter off solid product. White solid—49.34 g. Dry product at 95°C. full vacuum for 24 hours. Discharge from dryer. Chunky, white solid. Pulverize before bottling—14.62 g.

15 **Analytical Results:**

HPLC (Area % CI-1027)—99.60%

Water Content (KF titration)—4.93% (ave. of 2)

Calcium Content (ICP, corrected for water)—10.52%

XRD—CI-1027 Crystalline Form 2, see Figure 15.

20 As noted in the forgoing examples, the calcium salts of Formula II, in various solvated forms, are solid and many are highly crystalline, thus making them especially useful for commercial manufacture and formulation. This unique solid nature and crystallinity of the calcium salts is surprising, given that other

-32-

common salt forms have undesirable physical characteristics such as being hygroscopic and/or noncrystalline. Such hygroscopic and noncrystalline salt forms are unacceptable for large scale manufacturing and formulation operations. The following example further illustrates the advantages of the present calcium salts over the other salt forms.

EXAMPLE 14

Comparison of monoalkali earth salts to other salts

Following the general procedure of Example 1, 72953 was reacted with sodium hydroxide, potassium hydroxide, and acetylcholine in stoichiometric ratios of 1:1 per dialkanoic acid molecule, and 2:1 per dialkanoic acid molecule. The properties of the solids thus prepared, following complete drying, were compared to the calcium salt (CI-1027) from Example 1. The results are presented in Table 1.

TABLE 1
Salt Form and Hygroscopic Status

Salt Prepared	Physical Form	Physical Properties of Solid
di-sodium	Solid	Very Hygroscopic
di-potassium	Solid	Very Hygroscopic
mono-choline	Oil	-
di-choline	Oil	-
mono-sodium	Solid	Hygroscopic
mono-potassium	Solid	Very Hygroscopic
mono-calcium	Solid and/or Crystalline	None to Slight Hygroscopic

EXAMPLE 15

The effects of CI-1027 of Formula II, Crystalline Form 1, on Lp(a) and other lipoprotein parameters in two models of elevated Lp(a) were determined by the following in vivo assays

Cynomolgus macaque monkeys and Lp(a) transgenic mice are dosed with CI-1027 at 3, 10, 30, 100, or 300 mg/kg for 2 weeks by oral gavage. Lp(a)

-33-

lowering is dose dependent (-9, -23, -64, -68, and -87% for the 3, 10, 30, 100, and 300 mg/kg/day doses, respectively). In these studies total plasma and HDL cholesterol decreased. In the transgenic mouse study, female mice were allocated into five groups with equivalent Lp(a) levels, and dosed by oral gavage with either vehicle alone or vehicle plus CI-1027 (3, 10, 30, and 100 mg/kg/day). Blood is sampled weekly (2 weeks prior to treatment, 2 weeks on treatment). At the start of the study, plasma Lp(a) averaged 40 mg: (1 dL) across the groups. After 1 week, CI-1027 caused a dose dependent decrease in plasma Lp(a) (-15, -41, -54, and -61% for the 3, 10, 30, and 100 mg/kg/day dose levels, respectively) as compared to mice dosed with vehicle alone. There was also a dose-related decrease in total plasma cholesterol, with a maximum decrease of 32% at the 100 mg/day dose. Lipoprotein profiles determined by HPLC demonstrated that the decrease in cholesterol is due primarily to significant decreases in LDL cholesterol. HDL cholesterol remained unchanged. The ratio of HDL cholesterol to VLDL + LDL cholesterol improved with treatment from a control value of 0.39 to 0.65. Plasma apoB was also decreased by up to 30%. Changes are similar following the second week of treatment.

EXAMPLE 16

The effects of CI-1027 Crystal Form 1 on insulin sensitivity

CI-1027 is evaluated in a standard assay utilizing 3T3-L1 adipocytes, which are particularly responsive to insulin, ie. sugar uptake can be acutely activated 15- to 20-fold by insulin. The methodology utilized for the assay is described more fully by Frost, et al., *J Biol. Chem.*, 1985:260:2646-2652. Specifically, 3T3-L1 fibroblast cells were obtained from American Type Culture Collection (ATCC, Rockville, MD). Cells were grown to confluence and differentiated into adipocytes. On Day 0, confluent cells were treated with 167 nM insulin, 0.25 μ M dexamethasone, and 0.5 mM methyl isobutylmethylxanthine in 10% fetal bovine serum (FBS) containing Dulbecco's Modified Eagle's Medium (DMEM). Two days later, the media was changed to DMEM containing 167 nM insulin and 10% FBS. The media was then switched to 10% DMEM and changed every other day until harvest. CI-1027 solubilized in dimethyl sulfoxide, was included in the media on Day 0, and replenished with

-34-

each media change. Differentiation was assessed by visualizing the accumulation of fat droplets in the cells. Glucose transport was measured by quantitating the incorporation of [^{14}C]deoxyglucose in differentiated cells on Day 9, according to the methodology described by Sandouk, et al., *Endocrinology*, 1993:133:352-359.

EXAMPLE 17

Pharmacokinetics and metabolism of [^{14}C]CI-1027

CI-1027 is under clinical evaluation for the treatment of dyslipidemias and atherosclerosis by elevating high-density lipoprotein cholesterol (HDL-C) and lowering the atherogenic lipoprotein Lp(a). CI-1027 is rapidly absorbed in the rat, dog, and monkey. Oral bioavailability appeared to be high even though CI-1027 pharmacokinetics are nonlinear and the drug seemed to undergo enterohepatic recirculation. Apparent intravenous (IV) and per orals (PO) elimination half-life values are shorter in rat (5 to 7 hours) than in dog (17 to 31 hours) or in the monkey (9 to 15 hours). In vitro binding to plasma proteins is species and concentration dependent. Albumin appeared to be the primary binding protein. In vitro studies with rat, dog, and monkey hepatocytes using radiolabeled compound revealed two major ^{14}C peaks, intact drug, and a glucuronide conjugate. Mean recovery (percent ^{14}C dose) in intact and bile-fistula cannulated rats and monkeys following 10 mg/kg [^{14}C] is shown below in Table 2.

TABLE 2

Mean Recovery as Percent of 10 mg/kg and ^{14}C dose

Excreta	Intact Rat	Fistula Rat	Monkey	Fistula Monkey
Bile		87.5		42.0
Urine	37.0	10.5	78.1	62.2
Feces	56.9	0.72	17.3	3.82
Total	93.9	98.7	95.4	108

Metabolite profiling is performed by HPLC with radiometric detection and metabolites are identified by LC/RAM/MS/MS. Essentially 100% of the plasma

-35-

radioactivity was unchanged drug. Since an acyl-glucuronide is detected in bile and urine, LC/NMR analysis is performed to examine the potential acyl-migration products.

EXAMPLE 18

5 Capsule formulation

Ingredient	Amount
6-(5-carboxy-5-methyl-hexyloxy)- 2-dimethylhexanoic acid monocalcium salt hydrate Crystal Form 1	1000 g
Lactose	960 g
Magnesium Stearate	40 g

The ingredients are blended to uniformity and filled into #4 hard gelatin capsules. Each capsule is filled with 200 mg of the blended mixture and contains 100 mg of active monocalcium dicarboxylate ether. The capsules are administered to an adult human at the rate of one to three each day to lower plasma Lp(a).

EXAMPLE 19

10

Tablet formulation

Ingredient	Amount
6-(5-carboxy-5-methyl-hexyloxy)- 2,2-dimethyl-1-hexanoic acid monocalcium salt hydrate Crystal Form 2	3000 g
Lactose	750 g
Cornstarch	300 g
Gelatin	120 g
Water	1000 cc
Magnesium stearate	20 g

-36-

The dialkyl ether salt, lactose, and 150 g of the cornstarch are blended with a solution of the gelatin in the water. The wet granulation is screened, dried, and re-screened. The dried granules are blended with the magnesium stearate and the remaining cornstarch, and the mixture is compressed into 698 mg tablets using 15/32 inch standard concave punches. Each tablet contains 500 mg of dialkyl ether salt.

EXAMPLE 20

Oral liquid formulation

Ingredient	Amount
6-(5-carboxy-5-methyl-hexyloxy)-2, 2-dimethyl-1-hexanoic acid monocalcium salt hydrate Crystal Form 1	4.0 g
Polyoxyethylene sorbital monostearate	0.1 cc
Sodium carboxymethyl cellulose	0.3 g
Complex Magnesium Aluminum Silicate	0.5 g
Sugar	10 g
Glycerin	2 cc
Sodium benzoate	0.5 g
Sodium citrate	0.2 g
Approved red dye	1 mg
Cherry flavor	0.02 cc
Distilled water qs	100 cc

The polyoxyethylene sorbital monostearate is a product such as polysorbate 60 or Tween 60. The complex magnesium-aluminum silicate is a gel-forming agent, such as Vcegum H.V. This substance is hydrated overnight in 10 cc of distilled water. A mixture is prepared from the polyoxyethylene sorbital monostearate, imitation cherry flavor, 30 cc of distilled water, and the alkaline earth dicarboxylate ether and passed through a homogenizer. With vigorous stirring, the sugar, glycerin sodium citrate, sodium benzoate, and sodium carboxymethylcellulose are added, followed by a hydrated complex of

-37-

magnesium-aluminum silicate and a solution of the red dye in 2 cc of water. The resulting suspension is homogenized, adjusted to pH 5.0 with citric acid, and diluted to a final volume of 100 cc with distilled water. A 55-cc oral dosage unit of this suspension contains 100 mg of the dialkyl acid ether salt. If desired, the red dye and imitation cherry flavor can be omitted or replaced by other coloring and flavoring agents.

EXAMPLE 21

Coated tablet formulation

Ingredients	Amount for 1000 tablets
<u>Tablet Core</u>	
6-(5-carboxy-5-methyl-hexyloxy)-2, 2-dimethyl- 1-hexanoic acid monocalcium salt (CI-1027)	168.92
Lactose monohydrate NF	36.00
Hydroxypropyl cellulose	18.80
Croscarmellose sodium	9.40
Magnesium stearate (nonbovine)	1.88
Purified water, USP	qs
	<hr/> 235.00 g <hr/>

The tablet core is prepared in a fluid bed granulator. An aqueous binder solution of hydroxypropyl cellulose in water is placed in a low shear mixer. The CI-1027 and lactose monohydrate are blended together in the fluid bed granulator. The binder solution is sprayed over the top of the mixture in the fluid bed granulator to produce granules. The granules are collected and passed through a Comil. The screened granules are mixed with the croscarmellose sodium in a blender to uniformity. Magnesium stearate is added to the blender and the mixture is stirred to uniformity. The mixture is pressed into 1000 tablets using a standard tablet press. The tablets are mixed in a coating pan with a solution of 7.00 g of Opandry White YS-1-7040 (Colorcon Inc., West Point, Pennsylvania) and 0.05 g of simethicone emulsion USP (30% in water). The tablets are then coated with a

-38-

film that facilitates storage and administration. Each tablet contains 168.92 mg of CI-1027, which is equivalent to 150 mg of 72953 (free acid).

5 The invention and the manner and process of making and using it are now described in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, to make and use the same. It is to be understood that the foregoing describes preferred embodiments of the present invention, and that modifications may be made therein without departing from the spirit or scope of the present invention as set forth in the claims. To particularly point out and distinctly claim the subject matter regarded as invention, the following claims conclude this specification.=

10

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
21